FilgrastimGranulocyte Colony Stimulating factor (Oncology) Indication: 1. Cancer patients receiving myelosuppressive chemotherapy: Filgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. 2. Patients with Acute Myeloid Leukemia, receiving Induction or consolidation […]